Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
LiPlasome Pharma
company
About
LiPlasome, a biotech company focused on oncology, provides a liplasomal reformulation of anticancer drugs on the market.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $8.01M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2002
- Number Of Employee
- 11 - 50
- Operating Status
- Active
LiPlasome is a Danish privately owned biotech company focusing on oncology. The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCis®, Oxaliplatin -> LiPloxa.The aim is to provide more effective treatment to cancer patients with fewer side effects.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$8.01M
LiPlasome Pharma has raised a total of
$8.01M
in funding over 2 rounds. Their latest funding was raised on
Mar 1, 2005 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 1, 2005 | Series B | $8.01M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
LiPlasome Pharma is funded by 1 investors.
BankInvest Biomedical Venture
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
BankInvest Biomedical Venture
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
